Keyphrases
Acute Decompensated Heart Failure
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Sacubitril-valsartan
100%
Twice Daily
50%
Heart Failure
33%
Tolerability
33%
Failure Study
33%
New York Heart Association Functional Class
33%
Angiotensin Receptor-neprilysin Inhibitor
33%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
33%
Clinical Follow-up
16%
COVID-19
16%
Clinical Outcomes
16%
Patient Data
16%
Clinical Safety
16%
Area under the Curve
16%
Reduced Mortality
16%
Change from Baseline
16%
Heart Failure Patients
16%
Angiotensin-converting Enzyme Inhibitor (ACEi)
16%
Angiotensin Receptor Blockers
16%
Heart Failure Hospitalization
16%
COVID-19 Pandemic
16%
Data Integrity
16%
B-type Natriuretic Peptide
16%
Double Dummy
16%
Peptide Concentration
16%
Patient Safety
16%
Reduced Ejection Fraction
16%
Natriuretic Peptides
16%
Active Comparator
16%
Heart Failure Trials
16%
Proportional Changes
16%
Safety Efficacy
16%
Global Mortality
16%
Examination Results
16%
Valsartan
16%
LCZ696
16%
Days Open
16%
Safety Integrity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
100%
Valsartan/Sacubitril
100%
Natriuretic Factor
33%
Tolerability
22%
Enkephalinase Inhibitor
22%
Brain Natriuretic Peptide
11%
Dipeptidyl Carboxypeptidase Inhibitor
11%
Angiotensin Receptor Antagonist
11%
Angiotensin Receptor
11%
Sacubitril Plus Valsartan
11%
Valsartan
11%